Tryptamine Therapeutics listed in 2024 through the reverse takeover of Exopharm. Tryptamine Therapeutics is a clinical-stage biotechnology company focused on the development of an IV infusion of psilocin (the active metabolite of psilocybin) which addresses many of the current limitations associated with orally administered psilocybin used by the majority of competitors in the field. Tryp’s lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy.
Tryptamine Therapeutics
Follow
Get notifications in MyBN when activity occurs.
Company Activity
NEW ROLE: Jim Gilligan, | 02 Dec 2024 | |
NEW ROLE: Jim O'Neill, | 02 Dec 2024 | |
NEW ROLE: Chris Ntoumenopoulos, Non-Executive Director | 08 Aug 2024 | |
NEW ROLE: Mark Davies, Non-Executive Chairman, Non-Executive Director | 08 Aug 2024 | |
UPDATED: Public Companies - non WA list | 05 Jul 2024 | |
NEW ROLE: Clarke Barlow, Non-Executive Director | 17 Nov 2023 | |
RANKING: 918 Down from 701 in Public Companies - non WA list | 02 Oct 2023 |